Very low levels of ABCA7 in the cerebrum and Alzheimer’s disease onset between the ages of 60 and 80 independently of APOE
Journal of Neuropathology & Experimental Neurology · 2024
DOI: 10.1093/jnen/nlae060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2024. Verfasst von Viktor Garliyev und 4 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer's Center at Temple, Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States. Hauptthemen laut MEDLINE: Alzheimer Disease, ATP-Binding Cassette Transporters, Apolipoproteins E. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Michael J. Fox Foundation, Pennsylvania Department of Health, Commonwealth Universal Research Enhancement Program.
Themen: Demenz
Abstract (Originalsprache)
This cross-sectional study addressed the ABCA7-Alzheimer’s disease (AD) association. ABCA7 protein levels were quantified in 3 cerebral regions of brain donors with Braak neurofibrillary tangle (NFT) stages 0-V. Ordinal regression models were implemented to estimate the effect of ABCA7 on stopping in an earlier Braak NFT stage versus progressing to the later stages in 2 prespecified age segments. In the final model, high ABCA7 levels in the parietal cortex increased the odds of remaining cognitively healthy (ie, in stages 0/I) versus experiencing AD onset (ie, progressing to stages II-V) in the 61-80 age segment (OR = 2.87, adj 95% CI = 1.41-7.86, adj P = .007, n = 109), after controlling for APOE and other covariates. No ABCA7-AD association was found in the 81-98 age segment (n = 113). Parietal ABCA7 levels in 61-80-year-old with stages II-V were very low, even significantly lower than in 81-98-year-old with stages II-V. ABCA7 levels in the prefrontal cortex and hippocampus predicted AD onset in the 61-80 age segment after adjustment for APOE. ABCA7 levels were also the lowest in 61-80-year-old with frequent neuritic plaques. Thus, very low ABCA7 levels in the cerebrum are associated with AD onset in the 7th-8th decade of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Alzheimer's Center at Temple, Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States.
- Office of Institutional Research & Analysis, University of Pennsylvania, Philadelphia, PA, United States.
Förderung
- NIA NIH HHS
- Michael J. Fox Foundation
- Pennsylvania Department of Health, Commonwealth Universal Research Enhancement Program
- Michael J. Fox Foundation for Parkinson's Research to the Brain and Body Donation
- Arizona Department of Health Services
- Arizona Biomedical Research Commission
- NINDS NIH HHS
- Banner Sun Health Research Institute
Zitieren
APA
Garliyev, V., Lyssenko, C. A., Wiener, J. P., Praticò, D., & Lyssenko, N. N. (2024). Very low levels of ABCA7 in the cerebrum and Alzheimer’s disease onset between the ages of 60 and 80 independently of APOE. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlae060
Vancouver
Garliyev V, Lyssenko CA, Wiener JP, Praticò D, Lyssenko NN. Very low levels of ABCA7 in the cerebrum and Alzheimer’s disease onset between the ages of 60 and 80 independently of APOE. Journal of Neuropathology & Experimental Neurology. 2024. doi:10.1093/jnen/nlae060
BibTeX
@article{Garliyev2024,
author = {Garliyev, Viktor and Lyssenko, Catherine A and Wiener, Joel P and Praticò, Domenico and Lyssenko, Nicholas N},
title = {Very low levels of ABCA7 in the cerebrum and Alzheimer’s disease onset between the ages of 60 and 80 independently of APOE},
journal = {Journal of Neuropathology & Experimental Neurology},
year = {2024},
doi = {10.1093/jnen/nlae060}
}
EUVIMED